Modality
Fusion Protein
MOA
VEGFi
Target
ALK
Pathway
Lipid Met
EoE
Development Pipeline
Preclinical
Dec 2020
→ May 2031
PreclinicalCurrent
NCT06485180
2,066 pts·EoE
2020-12→2031-05·Terminated
2,066 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-05-175.1y awayInterim· EoE
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
Preclinical
Termina…
Catalysts
Interim
2031-05-17 · 5.1y away
EoE
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06485180 | Preclinical | EoE | Terminated | 2066 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa | |
| Niralucimab | Ionis | Phase 1 | ALK | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R |